文章基本信息

标题：Breast cancer therapy and cardiovascular risk: focus on trastuzumab
本地全文：下载
作者：Video abstract presented by Aamer Sandoo. Views: Aamer Sandoo ; George D Kitas ; Amtul R Carmichael 等
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2015
卷号：11
页码：223-228
DOI：10.2147/VHRM.S69641
出版社：Dove Medical Press Ltd
摘要：Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer.
关键词：endothelial dysfunction; microvasculature; macrovasculature; congestive heart failure